EIF3L: A Protein Regulating Cell Division, Signaling and Survival

Target Name: EIF3L

NCBI ID: G51386

EIF3L

EIF3L: A Protein Regulating Cell Division, Signaling and Survival

EIF3L, short for Eukaryotic Initiation Factor 3-Like, is a protein that plays a critical role in the process of cell division and growth. It is a key regulator of the G1 phase of the cell cycle, which is the stage of growth and preparation for cell division. In recent years, researchers have discovered that EIF3L is involved in a wide range of cellular processes, including cell division, cell signaling, and cell survival.

One of the key functions of EIF3L is its role in cell signaling. It is a key regulator of the RAS/MAPK signaling pathway, which is a critical pathway that regulates cell proliferation, differentiation, and survival. This pathway is involved in the regulation of many cellular processes, including cell signaling, cell division, and cell survival.

Another important function of EIF3L is its role in cell division. It is a key regulator of the mitosis, the process by which a cell divides, and it is involved in the regulation of the metaphase, which is the stage of cell division where the chromosomes are replicated and the cell divides.

In addition to its role in cell signaling and cell division, EIF3L is also involved in the regulation of cell survival. It has been shown to play a key role in the regulation of cell apoptosis, which is the process by which cells die and are removed from the body. This is important for the regulation of many cellular processes, including the regulation of cell growth and the regulation of cell differentiation.

The research on EIF3L has identified it as a potential drug target and biomarker. Several studies have shown that inhibiting EIF3L can lead to a wide range of cellular and biological changes, including the inhibition of cell division, the inhibition of cell signaling, and the inhibition of cell survival. This suggests that EIF3L may be a useful target for the treatment of many diseases, including cancer, neurodegenerative diseases, and diseases that involve cellular dysfunction.

In conclusion, EIF3L is a protein that plays a critical role in the process of cell division and growth. It is involved in the regulation of cell signaling, cell division, and cell survival, and has been shown to be a potential drug target and biomarker. Further research is needed to fully understand the role of EIF3L in cellular processes and to develop effective treatments for diseases that involve cellular dysfunction.

Protein Name: Eukaryotic Translation Initiation Factor 3 Subunit L

Functions: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17581632, PubMed:25849773, PubMed:27462815). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17581632). The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773)

The "EIF3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF3L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets